06/08/2025: The Pager Plot, A Psychedelic Journey, Mr. Clooney Goes to Broadway
60 Minutes - A podcast by CBS News - Mondays

Categories:
For the first time, ex-Mossad agents who led the exploding pager and walkie-talkie plot against Hezbollah, which garnered worldwide attention in September, detail their 10-year undercover op in an interview with correspondent Lesley Stahl. Meeting in Israel, the agents, who recently retired from service, share never-before-known details that caught Hezbollah fighters by surprise and ultimately spurred change across the region from Lebanon to Syria to Iran. Last year, the Veterans Administration announced it would begin funding clinical trials to explore the use of psychedelic drugs for treating post-traumatic stress disorder, depression and addiction. However, these trials are small, and even if successful, it will likely be years before veterans can access psychedelics at the VA. Many U.S. veterans struggling with PTSD aren’t waiting. Thousands of them are traveling overseas seeking relief at psychedelic retreats where these substances are legal to use, mostly in indigenous ceremonies. Correspondent Anderson Cooper follows nine veterans on a psychedelic journey to the west coast of Mexico, where they hope to find healing. Correspondent Jon Wertheim goes behind the scenes as George Clooney makes his Broadway debut, starring in an adaptation of the 2005 Oscar-nominated movie “Good Night, and Good Luck.” Clooney co-wrote both the original screenplay and this play, which tell the story of pioneering journalist Edward R. Murrow, who took on Senator Joseph McCarthy. Clooney calls it a fight for the ages and says the plot, which revolves around themes of truth, intimidation and courage in corporate media, resonates today. Now 64, the actor tells Wertheim why he finally feels ready to take on the role of Murrow himself. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices